These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 24565283)
1. Optimising the use of mTOR inhibitors in renal transplantation. Russ GR Transplant Res; 2013 Nov; 2(Suppl 1):S4. PubMed ID: 24565283 [TBL] [Abstract][Full Text] [Related]
2. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity. Tönshoff B; Höcker B Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497 [TBL] [Abstract][Full Text] [Related]
3. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Höcker B; Tönshoff B Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600 [TBL] [Abstract][Full Text] [Related]
4. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors. Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590 [TBL] [Abstract][Full Text] [Related]
5. Clinical insights for cancer outcomes in renal transplant patients. Alberú J Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450 [TBL] [Abstract][Full Text] [Related]
6. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Flechner SM; Kobashigawa J; Klintmalm G Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899 [TBL] [Abstract][Full Text] [Related]
7. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience. Sert M; Celik A; Kural K; Ersan S; Ataca P; Atila K; Cavdar C; Sifil A; Bora S; Gulay H; Camsari T Ren Fail; 2011; 33(8):789-94. PubMed ID: 21787153 [TBL] [Abstract][Full Text] [Related]
8. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Cotterell AH; Fisher RA; King AL; Gehr TW; Dawson S; Sterling RK; Stravitz RT; Luketic VA; Sanyal AJ; Shiffman ML; Posner MP Clin Transplant; 2002; 16 Suppl 7():49-51. PubMed ID: 12372044 [TBL] [Abstract][Full Text] [Related]
9. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation. Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744 [TBL] [Abstract][Full Text] [Related]
10. Treatment strategies to minimize or prevent chronic allograft dysfunction in pediatric renal transplant recipients: an overview. Höcker B; Tönshoff B Paediatr Drugs; 2009; 11(6):381-96. PubMed ID: 19877724 [TBL] [Abstract][Full Text] [Related]
12. Immunosuppression Minimization and Avoidance Protocols: When Less Is Not More. Prashar R; Venkat KK Adv Chronic Kidney Dis; 2016 Sep; 23(5):295-300. PubMed ID: 27742383 [TBL] [Abstract][Full Text] [Related]
13. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure. Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B; Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318 [TBL] [Abstract][Full Text] [Related]
14. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology. Stevens RB; Foster KW; Miles CD; Kalil AC; Florescu DF; Sandoz JP; Rigley TH; Malik T; Wrenshall LE PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152 [TBL] [Abstract][Full Text] [Related]
15. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients. Mulgaonkar S; Kaufman DB Clin Transplant; 2014 Nov; 28(11):1209-24. PubMed ID: 25142257 [TBL] [Abstract][Full Text] [Related]
16. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [TBL] [Abstract][Full Text] [Related]
17. Systemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant. Kumar J; Reccia I; Kusano T; Julie BM; Sharma A; Halawa A World J Transplant; 2017 Apr; 7(2):144-151. PubMed ID: 28507917 [TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Marcén R Drugs; 2009 Nov; 69(16):2227-43. PubMed ID: 19852526 [TBL] [Abstract][Full Text] [Related]